Revenue Recognition - Narrative (Details) - USD ($) $ in Thousands			1 Months Ended	3 Months Ended		9 Months Ended		93 Months Ended
	Jul. 06, 2021	May 05, 2020	Jan. 31, 2015	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Prior period performance obligation revenue recognized						$ 27,800	$ 36,000
Overpayment reimbursement liability				$ 1,300		1,300		$ 1,300	$ 5,000
Revenue recognized						73
Total revenues				179,744	$ 385,813	818,856	1,373,387
Rayaldee
Disaggregation of Revenue [Line Items]
Revenue recognized				6,900	8,500	18,200	19,300
Total revenues				14,497	15,332	43,358	47,099
Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues				4,500	8,768	97,659	22,585
Products | Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues		$ 3,000
Pfizer | Products
Disaggregation of Revenue [Line Items]
Revenue recognized								$ 85,000
Maximum milestone payments			$ 275,000
Initial upfront payment			$ 295,000
Pfizer | Products | Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues				2,200	$ 2,500	6,800	8,100
Maximum milestone payments						85,000
NGENLA (Somatrogon) and Pfizer’s Genotropin
Disaggregation of Revenue [Line Items]
Proceeds from royalty payments				$ 1,400		1,400
VFMCRP | Products | Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues						$ 3,000
LeaderMed | Products | Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues							1,000
CAMP4 | Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues	$ 1,500
CAMP4 | Products | Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues							4,900
Nicoya
Disaggregation of Revenue [Line Items]
Initial upfront payment							$ 5,000